"use strict";(self.webpackChunkngsw_docs_cnv_en=self.webpackChunkngsw_docs_cnv_en||[]).push([[3],{3905:function(e,t,a){a.d(t,{Zo:function(){return m},kt:function(){return u}});var i=a(67294);function n(e,t,a){return t in e?Object.defineProperty(e,t,{value:a,enumerable:!0,configurable:!0,writable:!0}):e[t]=a,e}function r(e,t){var a=Object.keys(e);if(Object.getOwnPropertySymbols){var i=Object.getOwnPropertySymbols(e);t&&(i=i.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),a.push.apply(a,i)}return a}function o(e){for(var t=1;t<arguments.length;t++){var a=null!=arguments[t]?arguments[t]:{};t%2?r(Object(a),!0).forEach((function(t){n(e,t,a[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(a)):r(Object(a)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(a,t))}))}return e}function s(e,t){if(null==e)return{};var a,i,n=function(e,t){if(null==e)return{};var a,i,n={},r=Object.keys(e);for(i=0;i<r.length;i++)a=r[i],t.indexOf(a)>=0||(n[a]=e[a]);return n}(e,t);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);for(i=0;i<r.length;i++)a=r[i],t.indexOf(a)>=0||Object.prototype.propertyIsEnumerable.call(e,a)&&(n[a]=e[a])}return n}var l=i.createContext({}),p=function(e){var t=i.useContext(l),a=t;return e&&(a="function"==typeof e?e(t):o(o({},t),e)),a},m=function(e){var t=p(e.components);return i.createElement(l.Provider,{value:t},e.children)},c={inlineCode:"code",wrapper:function(e){var t=e.children;return i.createElement(i.Fragment,{},t)}},d=i.forwardRef((function(e,t){var a=e.components,n=e.mdxType,r=e.originalType,l=e.parentName,m=s(e,["components","mdxType","originalType","parentName"]),d=p(a),u=n,g=d["".concat(l,".").concat(u)]||d[u]||c[u]||r;return a?i.createElement(g,o(o({ref:t},m),{},{components:a})):i.createElement(g,o({ref:t},m))}));function u(e,t){var a=arguments,n=t&&t.mdxType;if("string"==typeof e||n){var r=a.length,o=new Array(r);o[0]=d;var s={};for(var l in t)hasOwnProperty.call(t,l)&&(s[l]=t[l]);s.originalType=e,s.mdxType="string"==typeof e?e:n,o[1]=s;for(var p=2;p<r;p++)o[p]=a[p];return i.createElement.apply(null,o)}return i.createElement.apply(null,a)}d.displayName="MDXCreateElement"},16392:function(e,t,a){a.r(t),a.d(t,{frontMatter:function(){return s},contentTitle:function(){return l},metadata:function(){return p},toc:function(){return m},default:function(){return d}});var i=a(87462),n=a(63366),r=(a(67294),a(3905)),o=["components"],s={sidebar_position:9,sidebar_label:"Glioma Report"},l="Glioma Report",p={unversionedId:"results/glioma-report",id:"results/glioma-report",isDocsHomePage:!1,title:"Glioma Report",description:"Glioma report is a clinical report on the characteristics of gliomas (including recurrent glioblastoma)",source:"@site/docs/results/glioma-report.mdx",sourceDirName:"results",slug:"/results/glioma-report",permalink:"/ngsw-docs-en/results/glioma-report",tags:[],version:"current",sidebarPosition:9,frontMatter:{sidebar_position:9,sidebar_label:"Glioma Report"},sidebar:"tutorialSidebar",previous:{title:"Bioinformatic Report",permalink:"/ngsw-docs-en/results/bioinformatic-report"},next:{title:"Coverage Analysis",permalink:"/ngsw-docs-en/results/coverage-analysis"}},m=[{value:"Applicability to Analysis of Other Pathologies",id:"applicability-to-other-pathologies",children:[]},{value:"Patient Info",id:"patient-info",children:[]},{value:"1. Somatic Mutations Report",id:"somatic-mutations-report",children:[{value:"Tumor Sample Info",id:"tumor-sample-info",children:[]},{value:"Tier I: Variants of Strong Clinical Significance",id:"tier-i",children:[]},{value:"Tier II: Variants of Potential Clinical Significance",id:"tier-ii",children:[]},{value:"Immunotherapy Markers",id:"immunotherapy-markers",children:[]},{value:"Suggested Diagnosis",id:"suggested-diagnosis",children:[]},{value:"Suggested Drugs",id:"suggested-drugs",children:[]},{value:"Mutations Details",id:"mutations-details",children:[]},{value:"Tier III: Mutations in Other Cancer-Panel Genes",id:"tier-iii",children:[]},{value:"Clinical Trials",id:"clinical-trials",children:[]},{value:"Glioma Genes Panel Details",id:"glioma-genes-panel-details",children:[]}]},{value:"2. Germline Variants Report",id:"germline-variants-report",children:[{value:"Control Sample Info",id:"control-sample-info",children:[]},{value:"Pathogenic or Likely Pathogenic for Gliomas",id:"pathogenic-or-likely-pathogenic-for-glioma",children:[]},{value:"ACMG secondary findings",id:"acmg-secondary-findings",children:[]},{value:"Pathogenic or Likely Pathogenic for Any Other Genes/Diseases",id:"pathogenic-or-likely-pathogenic-for-others",children:[]},{value:"Glioma Associated",id:"glioma-associated",children:[]}]},{value:"3. Reference List",id:"reference-list",children:[]},{value:"4. Technical Limitations",id:"technical-limitations",children:[]}],c={toc:m};function d(e){var t=e.components,s=(0,n.Z)(e,o);return(0,r.kt)("wrapper",(0,i.Z)({},c,s,{components:t,mdxType:"MDXLayout"}),(0,r.kt)("h1",{id:"glioma-report"},"Glioma Report"),(0,r.kt)("p",null,"Glioma report is a clinical report on the characteristics of gliomas (including recurrent glioblastoma)\nbased on the onco-markers discovered in samples and a base built on the basis of expert knowledge and\nscientific publications on this topic."),(0,r.kt)("div",{className:"admonition admonition-caution alert alert--warning"},(0,r.kt)("div",{parentName:"div",className:"admonition-heading"},(0,r.kt)("h5",{parentName:"div"},(0,r.kt)("span",{parentName:"h5",className:"admonition-icon"},(0,r.kt)("svg",{parentName:"span",xmlns:"http://www.w3.org/2000/svg",width:"16",height:"16",viewBox:"0 0 16 16"},(0,r.kt)("path",{parentName:"svg",fillRule:"evenodd",d:"M8.893 1.5c-.183-.31-.52-.5-.887-.5s-.703.19-.886.5L.138 13.499a.98.98 0 0 0 0 1.001c.193.31.53.501.886.501h13.964c.367 0 .704-.19.877-.5a1.03 1.03 0 0 0 .01-1.002L8.893 1.5zm.133 11.497H6.987v-2.003h2.039v2.003zm0-3.004H6.987V5.987h2.039v4.006z"}))),"caution")),(0,r.kt)("div",{parentName:"div",className:"admonition-content"},(0,r.kt)("p",{parentName:"div"},"The results of the report should be interpreted using all available clinical and laboratory data and\nshould not be used in isolation for diagnosis and treatment."))),(0,r.kt)("p",null,"Glioma report is generated for the sample if the following conditions are met:"),(0,r.kt)("ol",null,(0,r.kt)("li",{parentName:"ol"},"The sample is uploaded as a tumor tissue sample."),(0,r.kt)("li",{parentName:"ol"},'The sample analysis was successfully completed (that is, all stages of the analysis have the status "Complete").'),(0,r.kt)("li",{parentName:"ol"},'For a single tumor sample (tumor-only), at least one of the following stages was successfully completed:\n"Somatic SNVs/Indels annotation", "Germline SNVs/Indels annotation", or "Copy number variations discovery".\nIf you have a set of tumor and corresponding non-tumor samples (tumor-normal), then it is necessary that the\n"Somatic SNVs/Indels annotation" stage was successfully completed for tumor sample, and "Germline SNVs/Indels\nannotation" stage was successfully completed for normal sample.'),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/main-templates#glioma-report"},"The corresponding report template")," is created\n(before the sample was processed) and active.")),(0,r.kt)("h2",{id:"applicability-to-other-pathologies"},"Applicability to Analysis of Other Pathologies"),(0,r.kt)("p",null,"The report contains both information specific to gliomas and sections that can be used to present\nthe analysis results of other pathologies."),(0,r.kt)("p",null,(0,r.kt)("strong",{parentName:"p"},"Sections specific to gliomas:")),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-i"},"Tier I: Variants of Strong Clinical Significance"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-ii"},"Tier II: Variants of Potential Clinical Significance"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#suggested-diagnosis"},"Suggested diagnosis"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#suggested-drugs"},"Suggested drugs"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#mutations-details"},"Mutations details"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-iii"},"Tier III: Mutations in other Cancer-panel genes"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#glioma-genes-panel-details"},"Glioma genes panel details"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#pathogenic-or-likely-pathogenic-for-glioma"},"Pathogenic or likely pathogenic for gliomas"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#pathogenic-or-likely-pathogenic-for-others"},"Pathogenic or likely pathogenic for any other genes/diseases"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#glioma-associated"},"Glioma associated"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#reference-list"},"Reference list"),".")),(0,r.kt)("p",null,(0,r.kt)("strong",{parentName:"p"},"Sections not specific to gliomas:")),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#patient-info"},"Patient info"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tumor-sample-info"},"Tumor sample info"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#immunotherapy-markers"},"Immunotherapy markers"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#clinical-trials"},"Clinical trials"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#control-sample-info"},"Control sample info"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#acmg-secondary-findings"},"ACMG secondary findings"),";"),(0,r.kt)("li",{parentName:"ul"},(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#technical-limitations"},"Technical limitations"),".")),(0,r.kt)("h2",{id:"patient-info"},"Patient Info"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Patient info" template block'),"."),(0,r.kt)("li",{parentName:"ul"},"Contains basic data about the patient: Patient ID, Last name, First name, Date of birth, Sex, Diagnosis.\nYou can also add fields with patient Middle name, Age, Date of diagnosis and Comments\nin ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#edit-block"},"the report template"),"."),(0,r.kt)("li",{parentName:"ul"},"Section fields can be filled in or edited on the report page, on ",(0,r.kt)("a",{parentName:"li",href:"/add-patient#patient-info"},"the patient page"),",\nor on ",(0,r.kt)("a",{parentName:"li",href:"/results/main/snvs-indels/snv-details-page#sample-tab"},'"Sample" tab')," of the variant details page.\nInformation is updated in the report automatically, regardless of where the data was updated.")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(80114).Z,width:"800"})),(0,r.kt)("h2",{id:"somatic-mutations-report"},"1. Somatic Mutations Report"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"This section contains information obtained from the tumor sample analysis.")),(0,r.kt)("h3",{id:"tumor-sample-info"},"Tumor Sample Info"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Sample info" template block'),"."),(0,r.kt)("li",{parentName:"ul"},"Contains basic data about the tumor sample: Sequencing type, Sample collection date, Capture Kit, Sample\nlocation (Organ), Methodology. You can also add fields with sample Short name, Sample type, Oncological\ndisease, Onco stage, Onco stage details, Therapy line and Comments\nin ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#edit-block"},"the report template"),"."),(0,r.kt)("li",{parentName:"ul"},"Section fields can be filled in or edited on the report page,\non ",(0,r.kt)("a",{parentName:"li",href:"/results/main/main#sample-info"},"the tumor sample page"),",\nor on ",(0,r.kt)("a",{parentName:"li",href:"/results/main/snvs-indels/snv-details-page#sample-tab"},'"Sample" tab')," of the variant details page.\nInformation is updated in the report automatically, regardless of where the data was updated.")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(44673).Z,width:"800"})),(0,r.kt)("h3",{id:"tier-i"},"Tier I: Variants of Strong Clinical Significance"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Tier I variants" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if somatic variants were discovered and successfully annotated in the tumor sample\n("Somatic SNVs/Indels discovery" and "Somatic SNVs/Indels annotation" stages).'),(0,r.kt)("li",{parentName:"ul"},"Contains onco-markers (somatic single nucleotide variants, indels, copy number variations and structural\nvariations) of strong clinical significance associated with gliomas discovered in a tumor sample. Such onco-markers\nare very important for diagnostics and treatment of gliomas (Tier I).")),(0,r.kt)("h4",{id:"snvs-and-indels"},"Hereinafter, single nucleotide variants and indels are presented as following:"),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(21185).Z,width:"900"})),(0,r.kt)("ol",null,(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Gene")," is the common name of the gene in which the variant is located.\nIf you click on a gene, you will see a window with all the gene transcripts:")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(27922).Z,width:"600"})),(0,r.kt)("p",null,"You can find the description of the transcripts' table columns\nin ",(0,r.kt)("a",{parentName:"p",href:"/results/main/snvs-indels/snv-details-panel#transcripts"},'the description of "Transcripts" section on the variant details panel'),"."),(0,r.kt)("ol",{start:2},(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Position")," is a coordinate of the variant in the genome (chromosome + start position)."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Genetic variant")," is the nucleotide and amino acid substitutions\nusing ",(0,r.kt)("a",{parentName:"li",href:"https://varnomen.hgvs.org/"},"the HGVS notation"),". Nucleotide substitution: \u201cc.\u201d (coding; for a\nsubstitution in the coding sequence) or \u201cn.\u201d (non-coding; for a substitution in the non-coding sequence) prefix +\ngenomic position of the substituted nucleotide + reference allele > alternative allele.\nAmino acid substitution: \u201cp.\u201d prefix (protein) + reference amino acid + amino acid position in protein + new\namino acid resulting from the substitution."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Transcript")," is the main transcript ID from the ",(0,r.kt)("a",{parentName:"li",href:"https://www.ncbi.nlm.nih.gov/nuccore/"},"RefSeq"),' database\n(NM_xxxxxx.x). If you click on a transcript, you will see the same window with all the gene transcripts, as when\nyou click on the "Gene" field.'),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Consequence")," is the effect of the variant on genes. A detailed description of the possible values\ncan be found ",(0,r.kt)("a",{parentName:"li",href:"/results/main/snvs-indels/variant-viewer#variant-consequences"},"here"),"."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Allele frequency")," is an alternative allele frequency for the sample (in percentages)."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Coverage depth")," is a sequencing depth; the total number of reads of the sequence overlapping the variant\nposition for the sample."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"External links")," are links to pages with variant information in ",(0,r.kt)("a",{parentName:"li",href:"https://www.ncbi.nlm.nih.gov/snp/"},"dbSNP"),",\n",(0,r.kt)("a",{parentName:"li",href:"https://preview.ncbi.nlm.nih.gov/clinvar/"},"ClinVar")," and ",(0,r.kt)("a",{parentName:"li",href:"https://cancer.sanger.ac.uk/cosmic/"},"COSMIC")," (if\nit was ",(0,r.kt)("a",{parentName:"li",href:"/settings/custom-annotations#define-annotation-type"},"uploaded as a custom annotation"),")."),(0,r.kt)("li",{parentName:"ol"},"Links to the variant in embedded services: ",(0,r.kt)("img",{src:a(79321).Z,width:"30"})," is a module for visualization of variant on the genome, ",(0,r.kt)("img",{src:a(30643).Z,width:"20"})," is\na variant details page in SNV Viewer\n(",(0,r.kt)("a",{parentName:"li",href:"/results/main/snvs-indels/snv-details-page/#annotation-tab"},'"Annotation" tab'),").")),(0,r.kt)("p",null,(0,r.kt)("strong",{parentName:"p"},"Hereinafter, structural and copy number variations presented as following:")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(45293).Z,width:"900"})),(0,r.kt)("ol",null,(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Locus")," is the genome region affected by the variation (gene, chromosome, chromosome arm)."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"SV type"),": deletion, duplication, inversion, translocation, amplification (for structural variations) and\ncopy number gain/loss (for copy number variations)."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Location")," is the variation coordinates in the genome (chromosome (if the entire chromosome is affected);\nchromosome + arm; chromosome + start and final positions on it).")),(0,r.kt)("h3",{id:"tier-ii"},"Tier II: Variants of Potential Clinical Significance"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Tier II variants" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if somatic variants were discovered and successfully annotated in the tumor sample\n("Somatic SNVs/Indels discovery" and "Somatic SNVs/Indels annotation" stages).'),(0,r.kt)("li",{parentName:"ul"},"Contains onco-markers (somatic single nucleotide variants, indels, copy number variations and structural\nvariations) of potential clinical significance discovered in a tumor sample. These variations are likely\nassociated with gliomas, but this association is less well studied\ncompared to ",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-i"},"Tier I variations"),".")),(0,r.kt)("h3",{id:"immunotherapy-markers"},"Immunotherapy Markers"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Immunotherapy markers" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if tumor sample was uploaded in FASTQ or BAM format and the\nsomatic variants were discovered and successfully annotated in this sample\n("Somatic SNVs/Indels discovery" and "Somatic SNVs/Indels annotation" stages).'),(0,r.kt)("li",{parentName:"ul"},"Contains a calculated tumor mutation burden (TMB) level, which is the average number of non-inherited somatic\nmutations per million bases (Mb). High TMB (more than 19 mutations per 1 Mb) may predict response to\nimmunotherapy, and low TMB (less than 6 mutations per 1 Mb) may predict no susceptibility to immunotherapy.")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(74878).Z,width:"200"})),(0,r.kt)("h3",{id:"suggested-diagnosis"},"Suggested Diagnosis"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Suggested diagnosis" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if tumor sample was uploaded in FASTQ or BAM format and the somatic variants were\ndiscovered and successfully annotated ("Somatic SNVs/Indels discovery" and "Somatic SNVs/Indels annotation"\nstages) and the copy number variations were successfully discovered ("Copy number variations discovery" stage)\nin this sample.'),(0,r.kt)("li",{parentName:"ul"},"Contains a suggested diagnosis based on ",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-i"},"Tier I"),"\nand ",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-ii"},"Tier II")," mutations discovered in the sample and a knowledge\nbase containing more than 170 markers (single nucleotide variants, indels, structural variations, copy number\nvariations) associated with glioma. Suggestions are made under the assumption that the tumor sample DNA has\nbeen extracted from glioma. In case of uncertainty, up to three most probable diagnosis suggestions are proposed."),(0,r.kt)("li",{parentName:"ul"},"For a specific diagnosis, there are a rationale as a list of Tier I and Tier II markers, the predicted survival\ntimes with excerpts from the publications from which the prediction was made, and links to publications.")),(0,r.kt)("div",{className:"admonition admonition-caution alert alert--warning"},(0,r.kt)("div",{parentName:"div",className:"admonition-heading"},(0,r.kt)("h5",{parentName:"div"},(0,r.kt)("span",{parentName:"h5",className:"admonition-icon"},(0,r.kt)("svg",{parentName:"span",xmlns:"http://www.w3.org/2000/svg",width:"16",height:"16",viewBox:"0 0 16 16"},(0,r.kt)("path",{parentName:"svg",fillRule:"evenodd",d:"M8.893 1.5c-.183-.31-.52-.5-.887-.5s-.703.19-.886.5L.138 13.499a.98.98 0 0 0 0 1.001c.193.31.53.501.886.501h13.964c.367 0 .704-.19.877-.5a1.03 1.03 0 0 0 .01-1.002L8.893 1.5zm.133 11.497H6.987v-2.003h2.039v2.003zm0-3.004H6.987V5.987h2.039v4.006z"}))),"caution")),(0,r.kt)("div",{parentName:"div",className:"admonition-content"},(0,r.kt)("p",{parentName:"div"},"All interpretations are based on published research and are provided for informational purposes only.\nThey are not intended to be a substitute for professional medical advice, diagnosis, or treatment."))),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(86784).Z,width:"900"})),(0,r.kt)("h3",{id:"suggested-drugs"},"Suggested Drugs"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Suggested drugs" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if the somatic variants were discovered and successfully annotated in the tumor sample\n("Somatic SNVs/Indels discovery" and "Somatic SNVs/Indels annotation" stages).'),(0,r.kt)("li",{parentName:"ul"},"Contains tumor-targeting drugs that are potentially effective and ineffective against glioma,\nselected in ",(0,r.kt)("a",{parentName:"li",href:"https://civicdb.org/statistics/drugs"},"CIVIC")," and ",(0,r.kt)("a",{parentName:"li",href:"https://www.cancergenomeinterpreter.org"},"CGI")," databases\nbased on the biomarkers discovered in the sample."),(0,r.kt)("li",{parentName:"ul"},"For each drug there is a table with the following columns:")),(0,r.kt)("ol",null,(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Markers")," are biomarkers (single nucleotide variant, indel, structural variation or copy number variation) of\n",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-i"},"Tier I")," or ",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-ii"},"Tier II")," that were discovered in the sample\nand which correspond to the drug."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Disease")," for treatment which the drug is approved (if the marker was discovered)."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Evidence level")," describes the reliability of the study supporting the evidence:")),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"A (validated association): a good research-based evidence to support association;"),(0,r.kt)("li",{parentName:"ul"},"B (clinical evidence): a fair research-based evidence to support association, confirmed by clinical trials\nor other primary data;"),(0,r.kt)("li",{parentName:"ul"},"C (case study): the association is shown in individual case reports from clinical journals;"),(0,r.kt)("li",{parentName:"ul"},"D (preclinical evidence): the association supported by ",(0,r.kt)("em",{parentName:"li"},"in vivo")," and ",(0,r.kt)("em",{parentName:"li"},"in vitro")," models.")),(0,r.kt)("ol",{start:4},(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"References"),": a link to a publication that confirms the drug as tumor-targeting if this marker\nis discovered.",(0,r.kt)("br",null),"For some markers, an excerpt from a publication with proof of association is provided.")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(95403).Z,width:"1000"})),(0,r.kt)("h3",{id:"mutations-details"},"Mutations Details"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Mutations details" template block'),"."),(0,r.kt)("li",{parentName:"ul"},"Includes ",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-i"},"Tier I")," and ",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#tier-ii"},"Tier II")," mutations\nwith excerpts from scientific publications confirming the association of the mutation with gliomas with links\nto the original publications.")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(64146).Z,width:"900"})),(0,r.kt)("h3",{id:"tier-iii"},"Tier III: Mutations in Other Cancer-Panel Genes"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Tier III variants" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if the somatic variants were discovered and successfully annotated in the tumor sample\n("Somatic SNVs/Indels discovery" and "Somatic SNVs/Indels annotation" stages).'),(0,r.kt)("li",{parentName:"ul"},"Contains onco-markers (somatic single nucleotide variants, indels, copy number variations and structural\nvariations) of high gene product impact detected in genes associated with cancers other than glioma (Tier III).")),(0,r.kt)("h3",{id:"clinical-trials"},"Clinical Trials"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Clinical trials" template block'),"."),(0,r.kt)("li",{parentName:"ul"},"Lists ongoing clinical trials of various interventions (drugs, devices, procedures, etc.) involving\npatients with a specific phenotype selected in the template block (in this case, glioma)\nfrom ",(0,r.kt)("a",{parentName:"li",href:"https://clinicaltrials.gov"},"ClinicalTrials")," database."),(0,r.kt)("li",{parentName:"ul"},"The table with clinical trials has the following columns:")),(0,r.kt)("ol",null,(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Title")," of the study with a link to a page with detailed information about\nit in ",(0,r.kt)("a",{parentName:"li",href:"https://clinicaltrials.gov"},"ClinicalTrials")," database."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Conditions")," is the disease, disorder, syndrome, illness, or injury being studied.\nIt may also include other health-related issues, such as lifespan, quality of life, and health risks."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Interventions")," are processes or actions that are the focus of a clinical study.\nInterventions include drugs, medical devices, procedures, vaccines, and other products that are either\ninvestigational or already available. Interventions can also include noninvasive approaches, such as education\nor modifying diet and exercise."),(0,r.kt)("li",{parentName:"ol"},(0,r.kt)("strong",{parentName:"li"},"Locations")," are locations of the studies (institution, city, country).")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(36e3).Z,width:"900"})),(0,r.kt)("h3",{id:"glioma-genes-panel-details"},"Glioma Genes Panel Details"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds\nto ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Glioma genes panel details" template block'),"."),(0,r.kt)("li",{parentName:"ul"},"Filled with data if tumor sample was uploaded in FASTQ or BAM format."),(0,r.kt)("li",{parentName:"ul"},"Contains information on coverage (fraction of the exonic part of the longest transcript covered by at least\n50 sequenced reads (50X)) of glioma-specific genes with strong or potential clinical significance related to glioma,\ndiscovered in the tumor sample. Shows an assessment of the completeness and quality of the source data for this\nreport. The higher the percent of coverage, the more completely a transcript is sequenced.")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(85513).Z,width:"900"})),(0,r.kt)("h2",{id:"germline-variants-report"},"2. Germline Variants Report"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"The section contains information obtained from the analysis of a non-tumor (control) sample.\nIt is support section containing germline variants that are pathogenic and/or associated with gliomas.")),(0,r.kt)("h3",{id:"control-sample-info"},"Control Sample Info"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds\nto ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Control (normal) sample info" template block'),"."),(0,r.kt)("li",{parentName:"ul"},"Filled with data if the analyzed sample set includes a non-tumor (control) sample in addition to the tumor sample."),(0,r.kt)("li",{parentName:"ul"},"Contains basic data about the control sample: Sequencing type, Sample collection date, Capture Kit, Sample\nlocation (Organ), Methodology. You can also add fields with sample Short name, Sample type, Oncological\ndisease, Onco stage, Onco stage details, Therapy line and Comments\nin ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#edit-block"},"the report template"),"."),(0,r.kt)("li",{parentName:"ul"},"Section fields can be filled in or edited on the report page,\non ",(0,r.kt)("a",{parentName:"li",href:"/results/main/main#sample-info"},"the non-tumor sample page"),",\nor on ",(0,r.kt)("a",{parentName:"li",href:"/results/main/snvs-indels/snv-details-page#sample-tab"},'"Sample" tab')," of the variant details page.\nInformation is updated in the report automatically, regardless of where the data was updated.")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(81487).Z,width:"800"})),(0,r.kt)("h3",{id:"pathogenic-or-likely-pathogenic-for-glioma"},"Pathogenic or Likely Pathogenic for Gliomas"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds\nto ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Germline pathogenic for gliomas" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if the germline variants were discovered and successfully annotated in a non-tumor (control)\nsample or a single tumor sample ("Germline SNVs/Indels discovery" and "Germline SNVs/Indels annotation" stages).'),(0,r.kt)("li",{parentName:"ul"},"Contains single nucleotide germline variants, discovered in the control sample and associated with gliomas\naccording to published research. These variants meet at least one of the following conditions:")),(0,r.kt)("ol",null,(0,r.kt)("li",{parentName:"ol"},"Marked as pathogenic in ",(0,r.kt)("a",{parentName:"li",href:"https://preview.ncbi.nlm.nih.gov/clinvar/"},"ClinVar"),";"),(0,r.kt)("li",{parentName:"ol"},"Marked as likely pathogenic in ",(0,r.kt)("a",{parentName:"li",href:"https://preview.ncbi.nlm.nih.gov/clinvar/"},"ClinVar"),";"),(0,r.kt)("li",{parentName:"ol"},"Have high gene product impact;"),(0,r.kt)("li",{parentName:"ol"},"Have moderate gene product impact and frequency less than 10% in population;"),(0,r.kt)("li",{parentName:"ol"},"Rare (have frequency less than 5% in population).")),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"In addition to the table described ",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#snvs-and-indels"},"above"),", for each variant,\nthere are excerpts from scientific publications confirming its association with gliomas with links to the publications.")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(55066).Z,width:"900"})),(0,r.kt)("h3",{id:"acmg-secondary-findings"},"ACMG secondary findings"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds\nto ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"SNVs/Indels in ACMG SF genes" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if the samples were uploaded in FASTQ or BAM formats or as VCF files (each with a single\nsample) and if germline variants were discovered and successfully annotated in a non-tumor (control) sample\nor a single tumor sample ("Germline SNVs/Indels discovery" and "Germline SNVs/Indels annotation" stages).'),(0,r.kt)("li",{parentName:"ul"},"Includes the variants discovered in the sample, which are located in the genes\nfrom ",(0,r.kt)("a",{parentName:"li",href:"https://www.ncbi.nlm.nih.gov/clinvar/docs/acmg/"},"the Secondary Findings (SF) list")," of\nAmerican College of Medical Genetics and Genomics (ACMG). For these genes, specific mutations are known to\nbe causative of disorders with defined phenotypes that are clinically actionable by an accepted intervention.\nThe ACMG recommends that variants detected in any of these genes should be reported as they are of medical\nrelevance and could be used in the future to inform clinical treatment."),(0,r.kt)("li",{parentName:"ul"},"The variants are divided into two lists according to the certain conditions,\nwhich are described in ",(0,r.kt)("a",{parentName:"li",href:"/results/acmg-sf-report#acmg-sf-content"},"the corresponding section"),".")),(0,r.kt)("div",{className:"admonition admonition-caution alert alert--warning"},(0,r.kt)("div",{parentName:"div",className:"admonition-heading"},(0,r.kt)("h5",{parentName:"div"},(0,r.kt)("span",{parentName:"h5",className:"admonition-icon"},(0,r.kt)("svg",{parentName:"span",xmlns:"http://www.w3.org/2000/svg",width:"16",height:"16",viewBox:"0 0 16 16"},(0,r.kt)("path",{parentName:"svg",fillRule:"evenodd",d:"M8.893 1.5c-.183-.31-.52-.5-.887-.5s-.703.19-.886.5L.138 13.499a.98.98 0 0 0 0 1.001c.193.31.53.501.886.501h13.964c.367 0 .704-.19.877-.5a1.03 1.03 0 0 0 .01-1.002L8.893 1.5zm.133 11.497H6.987v-2.003h2.039v2.003zm0-3.004H6.987V5.987h2.039v4.006z"}))),"caution")),(0,r.kt)("div",{parentName:"div",className:"admonition-content"},(0,r.kt)("p",{parentName:"div"},"Annotating variants with ClinVar to generate ACMG secondary findings report has the limitations\ndescribed ",(0,r.kt)("a",{parentName:"p",href:"/results/acmg-sf-report#acmg-sf-limitations"},"here"),"."))),(0,r.kt)("h3",{id:"pathogenic-or-likely-pathogenic-for-others"},"Pathogenic or Likely Pathogenic for Any Other Genes/Diseases"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Germline pathogenic for any other diseases" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if the germline variants were discovered and successfully annotated in a non-tumor (control)\nsample or a single tumor sample ("Germline SNVs/Indels discovery" and "Germline SNVs/Indels annotation" stages).'),(0,r.kt)("li",{parentName:"ul"},"Contains single nucleotide germline variants discovered in the sample, marked as pathogenic or likely\npathogenic in ",(0,r.kt)("a",{parentName:"li",href:"https://preview.ncbi.nlm.nih.gov/clinvar/"},"ClinVar")," and associated with diseases other than gliomas.")),(0,r.kt)("h3",{id:"glioma-associated"},"Glioma Associated"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds\nto ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Germline glioma associated" template block'),"."),(0,r.kt)("li",{parentName:"ul"},'Filled with data if the germline variants were discovered and successfully annotated in a non-tumor (control)\nsample or a single tumor sample ("Germline SNVs/Indels discovery" and "Germline SNVs/Indels annotation" stages).'),(0,r.kt)("li",{parentName:"ul"},"Contains single nucleotide germline variants discovered in the sample, associated with gliomas according to\npublished research, but not included\nin ",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#pathogenic-or-likely-pathogenic-for-glioma"},'"Pathogenic or likely pathogenic for gliomas" section'),"."),(0,r.kt)("li",{parentName:"ul"},"In addition to the table described ",(0,r.kt)("a",{parentName:"li",href:"/results/glioma-report#snvs-and-indels"},"above"),", for each variant,\nthere are excerpts from scientific publications confirming its association with gliomas with links to the publications.")),(0,r.kt)("p",{align:"center"},(0,r.kt)("img",{src:a(71749).Z,width:"900"})),(0,r.kt)("h2",{id:"reference-list"},"3. Reference List"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Glioma: Literature" template block'),"."),(0,r.kt)("li",{parentName:"ul"},"Contains links to articles, publications, and books related to glioma research that were used in compiling\nthe report.")),(0,r.kt)("h2",{id:"technical-limitations"},"4. Technical Limitations"),(0,r.kt)("ul",null,(0,r.kt)("li",{parentName:"ul"},"Corresponds to ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#block-types"},'"Disclaimer" template block'),"."),(0,r.kt)("li",{parentName:"ul"},"Contains a message about the limitations of the use of the report (the text can be edited\nin ",(0,r.kt)("a",{parentName:"li",href:"/settings/report-templates/report-templates#edit-block"},"the template"),").")))}d.isMDXComponent=!0},71749:function(e,t,a){t.Z=a.p+"assets/images/assosiated-5d38f9a60746166e710c970227391d55.png"},36e3:function(e,t,a){t.Z=a.p+"assets/images/clinical_trials-8194d49b80dd1348feacb8be9dea0cd6.png"},86784:function(e,t,a){t.Z=a.p+"assets/images/diagnosis-e61af62e7ea4704586dcf69b56eda617.png"},95403:function(e,t,a){t.Z=a.p+"assets/images/drugs-786905a4f3f97596b6594dda75f698d1.png"},85513:function(e,t,a){t.Z=a.p+"assets/images/gene_panels-b017f507ecaff3ffbd03abd909bd1fa3.png"},55066:function(e,t,a){t.Z=a.p+"assets/images/germline_pathogenic-329f7db436ef068fdeaf8d2c5d738127.png"},64146:function(e,t,a){t.Z=a.p+"assets/images/mutation-3b8c70f89894f8dda3848e60e5a47802.png"},81487:function(e,t,a){t.Z=a.p+"assets/images/normal_info-c389b6c09602d3524e64295fd23e547a.png"},80114:function(e,t,a){t.Z=a.p+"assets/images/patient_info-0123af93a86fd3edcd30f400c16243e3.png"},21185:function(e,t,a){t.Z=a.p+"assets/images/snvs_indels-fecf902155a1f1fcf828d1aacf465f16.png"},74878:function(e,t,a){t.Z=a.p+"assets/images/tmb-eeb7e402670fbe8248a848a7952ed7dd.png"},44673:function(e,t,a){t.Z=a.p+"assets/images/tumor_info-d9194bbf194419719cf70aada4f3cf16.png"},45293:function(e,t,a){t.Z=a.p+"assets/images/variations-1deac88cbb73a1ff5f8f7f0238069581.png"},79321:function(e,t){t.Z="data:image/png;base64,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"},30643:function(e,t){t.Z="data:image/png;base64,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"},27922:function(e,t,a){t.Z=a.p+"assets/images/transcripts-41cae82d7eb56e98382842cd1903341a.png"}}]);